Diagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective study
Abstract Background hPG80 (circulating progastrin), initially recognized for its oncogenic properties due to its direct link to the Wnt signaling pathway, is secreted by cancer cells and detectable in the blood of cancer patients. The ONCOPRO centralized case-control study (NCT03787056) was designed...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Biomarker Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40364-025-00793-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849402050896461824 |
|---|---|
| author | Benoit You Sebastien Couraud Philippe Ceruse Lionel Badet Philippe Paparel Alice Durand Marielle Guillet Philippe Merle Gaelle Lescuyer Charles-André Philip Francois Ducray Mathieu Pioche Lionel Karlin Jean-Christophe Lifante Olivier Glehen Pierre-Adrien Bolze Marion Chauvenet Carole Langlois-Jacques Fabien Subtil Marie Piecyk Aurore Carrot Dominique Joubert Alexandre Prieur Berengere Vire Sara Calattini Lea Payen |
| author_facet | Benoit You Sebastien Couraud Philippe Ceruse Lionel Badet Philippe Paparel Alice Durand Marielle Guillet Philippe Merle Gaelle Lescuyer Charles-André Philip Francois Ducray Mathieu Pioche Lionel Karlin Jean-Christophe Lifante Olivier Glehen Pierre-Adrien Bolze Marion Chauvenet Carole Langlois-Jacques Fabien Subtil Marie Piecyk Aurore Carrot Dominique Joubert Alexandre Prieur Berengere Vire Sara Calattini Lea Payen |
| author_sort | Benoit You |
| collection | DOAJ |
| description | Abstract Background hPG80 (circulating progastrin), initially recognized for its oncogenic properties due to its direct link to the Wnt signaling pathway, is secreted by cancer cells and detectable in the blood of cancer patients. The ONCOPRO centralized case-control study (NCT03787056) was designed to prospectively evaluate the diagnostic utility of hPG80 in patients with 16 different types of cancer. Methods hPG80 levels were measured in 421 patients with 16 newly diagnosed cancers (median age 65.6 years old) using the DxPG80.Lab kit (Biodena Care). The diagnostic performance of hPG80 (the primary endpoint) was assessed by comparing baseline hPG80 levels in cancer patients with those of 330 asymptomatic aged-matched healthy subjects from the general population. Results Between 2018 and 2022, a total of 506 cancer patients were enrolled in the study, with 421 assessable across 16 distinct cancer cohorts. hPG80 concentrations were significantly higher in cancer patients compared to the healthy population (median 3.8 [IQR: 1.0-11.1] vs. 1.9 [IQR: 0.6–4.2] pM, P < 0.0001). hPG80 levels were not impacted by renal failure, liver dysfunction, or cancer-associated inflammation. The diagnostic accuracy in cancer patients was ROC AUC 0.63, 95% CI = [0.59–0.67]. The highest diagnostic accuracy was seen in patients with lung cancer (AUC 0.75, 95% CI [0.68–0.82]; specificity = 88% for hPG80 > 7.73 pM in patients aged > 58 years old) and hepatocellular carcinoma HCC (ROC AUC 0.75, 95% CI [0.66-083]; specificity = 88% for hPG80 > 7.73 pM in patients aged > 58 years old). Conclusions This large prospective study confirms that cancer patients have significantly higher hPG80 blood concentration compared to the healthy population. Incorporating this straightforward ELISA assay into screening programs is warranted. Trial registration NCT03787056. |
| format | Article |
| id | doaj-art-25b373bb2362477ebeef50bd868652d1 |
| institution | Kabale University |
| issn | 2050-7771 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Biomarker Research |
| spelling | doaj-art-25b373bb2362477ebeef50bd868652d12025-08-20T03:37:38ZengBMCBiomarker Research2050-77712025-07-0113111110.1186/s40364-025-00793-zDiagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective studyBenoit You0Sebastien Couraud1Philippe Ceruse2Lionel Badet3Philippe Paparel4Alice Durand5Marielle Guillet6Philippe Merle7Gaelle Lescuyer8Charles-André Philip9Francois Ducray10Mathieu Pioche11Lionel Karlin12Jean-Christophe Lifante13Olivier Glehen14Pierre-Adrien Bolze15Marion Chauvenet16Carole Langlois-Jacques17Fabien Subtil18Marie Piecyk19Aurore Carrot20Dominique Joubert21Alexandre Prieur22Berengere Vire23Sara Calattini24Lea Payen25Lyon University Hospital, IC-HCL, Lyon UniversityLyon University Hospital, IC-HCL, Lyon UniversityLyon University Hospital, IC-HCL, Lyon UniversityLyon University Hospital, IC-HCL, Lyon UniversityLyon University Hospital, IC-HCL, Lyon UniversityLyon University Hospital, IC-HCL, Lyon UniversityLyon University Hospital, IC-HCL, Lyon UniversityLyon University Hospital, IC-HCL, Lyon UniversityLyon University Hospital, IC-HCL, Lyon UniversityLyon University Hospital, IC-HCL, Lyon UniversityLyon University Hospital, IC-HCL, Lyon UniversityLyon University Hospital, IC-HCL, Lyon UniversityLyon University Hospital, IC-HCL, Lyon UniversityLyon University Hospital, IC-HCL, Lyon UniversityLyon University Hospital, IC-HCL, Lyon UniversityLyon University Hospital, IC-HCL, Lyon UniversityLyon University Hospital, IC-HCL, Lyon UniversityLyon University Hospital, IC-HCL, Lyon UniversityLyon University Hospital, IC-HCL, Lyon UniversityLyon University Hospital, IC-HCL, Lyon UniversityLyon University Hospital, IC-HCL, Lyon UniversityProgastrin ManufacturingProgastrin ManufacturingProgastrin ManufacturingLyon University Hospital, IC-HCL, Lyon UniversityLyon University Hospital, IC-HCL, Lyon UniversityAbstract Background hPG80 (circulating progastrin), initially recognized for its oncogenic properties due to its direct link to the Wnt signaling pathway, is secreted by cancer cells and detectable in the blood of cancer patients. The ONCOPRO centralized case-control study (NCT03787056) was designed to prospectively evaluate the diagnostic utility of hPG80 in patients with 16 different types of cancer. Methods hPG80 levels were measured in 421 patients with 16 newly diagnosed cancers (median age 65.6 years old) using the DxPG80.Lab kit (Biodena Care). The diagnostic performance of hPG80 (the primary endpoint) was assessed by comparing baseline hPG80 levels in cancer patients with those of 330 asymptomatic aged-matched healthy subjects from the general population. Results Between 2018 and 2022, a total of 506 cancer patients were enrolled in the study, with 421 assessable across 16 distinct cancer cohorts. hPG80 concentrations were significantly higher in cancer patients compared to the healthy population (median 3.8 [IQR: 1.0-11.1] vs. 1.9 [IQR: 0.6–4.2] pM, P < 0.0001). hPG80 levels were not impacted by renal failure, liver dysfunction, or cancer-associated inflammation. The diagnostic accuracy in cancer patients was ROC AUC 0.63, 95% CI = [0.59–0.67]. The highest diagnostic accuracy was seen in patients with lung cancer (AUC 0.75, 95% CI [0.68–0.82]; specificity = 88% for hPG80 > 7.73 pM in patients aged > 58 years old) and hepatocellular carcinoma HCC (ROC AUC 0.75, 95% CI [0.66-083]; specificity = 88% for hPG80 > 7.73 pM in patients aged > 58 years old). Conclusions This large prospective study confirms that cancer patients have significantly higher hPG80 blood concentration compared to the healthy population. Incorporating this straightforward ELISA assay into screening programs is warranted. Trial registration NCT03787056.https://doi.org/10.1186/s40364-025-00793-zBiomarkers, tumorEarly detection of CancerWnt signaling pathwayProspective studies |
| spellingShingle | Benoit You Sebastien Couraud Philippe Ceruse Lionel Badet Philippe Paparel Alice Durand Marielle Guillet Philippe Merle Gaelle Lescuyer Charles-André Philip Francois Ducray Mathieu Pioche Lionel Karlin Jean-Christophe Lifante Olivier Glehen Pierre-Adrien Bolze Marion Chauvenet Carole Langlois-Jacques Fabien Subtil Marie Piecyk Aurore Carrot Dominique Joubert Alexandre Prieur Berengere Vire Sara Calattini Lea Payen Diagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective study Biomarker Research Biomarkers, tumor Early detection of Cancer Wnt signaling pathway Prospective studies |
| title | Diagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective study |
| title_full | Diagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective study |
| title_fullStr | Diagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective study |
| title_full_unstemmed | Diagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective study |
| title_short | Diagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective study |
| title_sort | diagnostic value of the wnt target and cancer associated blood biomarker hpg80 oncopro case control prospective study |
| topic | Biomarkers, tumor Early detection of Cancer Wnt signaling pathway Prospective studies |
| url | https://doi.org/10.1186/s40364-025-00793-z |
| work_keys_str_mv | AT benoityou diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT sebastiencouraud diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT philippeceruse diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT lionelbadet diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT philippepaparel diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT alicedurand diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT marielleguillet diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT philippemerle diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT gaellelescuyer diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT charlesandrephilip diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT francoisducray diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT mathieupioche diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT lionelkarlin diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT jeanchristophelifante diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT olivierglehen diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT pierreadrienbolze diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT marionchauvenet diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT carolelangloisjacques diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT fabiensubtil diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT mariepiecyk diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT aurorecarrot diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT dominiquejoubert diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT alexandreprieur diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT berengerevire diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT saracalattini diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy AT leapayen diagnosticvalueofthewnttargetandcancerassociatedbloodbiomarkerhpg80oncoprocasecontrolprospectivestudy |